Cigna Corporation (CI - Free Report) is set to report third-quarter 2021 results on Nov 4, before the opening bell.
Q3 Estimates
The Zacks Consensus Estimate for the company’s earnings is pegged at $5.23 per share, indicating a rise of 18.59% from the year-ago quarter’s reported figure.
The consensus mark for revenues stands at $42.96 billion, implying a rise of 5.28% from the prior-year quarter’s reported number.
Factors to Note
Strong performances across the company’s Evernorth, U.S. Medical and International Markets businesses are likely to have contributed to its to-be-reported quarter’s revenues.
The Evernorth unit might have gained momentum from a growing customer base and higher pharmacy scripts volumes in the to-be-reported quarter. Revenues are likely to have been driven by the insourcing of the U.S. Medical pharmacy volumes and strong organic growth including a rise in retail network and specialty pharmacy services.
Its U.S. Government business is likely to have gained from customer growth by continuing to expand its addressable markets.
The U.S. Medical business is likely to have benefited from customer growth across the company’s Select segment and Medicare Advantage business, and a rise in premiums and the return of the health insurance tax.
The International Markets business revenues are likely to have shown consistent business growth. Operating earnings might have been weighed on by costs incurred to support customers and employees, and investments made in the business for growth.
Numerous cost-curbing initiatives might have offset the company’s selling, general and administrativeexpenses to some extent in the to-be-reported quarter.
Earnings Surprise History
The company boasts an encouraging earnings surprise track. Its bottom line surpassed estimates in three of the trailing four quarters (missed the mark on the remaining occasion), the average surprise being 3.08%. This is depicted in the chart below:
What Our Quantitative Model Predicts
Our proven model does not predict an earnings beat for Cigna this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here.
Earnings ESP: Cigna has an Earnings ESP of -1.45%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Cigna currently carries a Zacks Rank #3.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Among other health insurers that have reported third-quarter results so far, the bottom-line results of UnitedHealth Group Inc. (UNH - Free Report) , Humana Inc. (HUM - Free Report) and Anthem Inc. beat the respective estimates.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Cigna Corporation (CI - Free Report) is set to report third-quarter 2021 results on Nov 4, before the opening bell.
Q3 Estimates
The Zacks Consensus Estimate for the company’s earnings is pegged at $5.23 per share, indicating a rise of 18.59% from the year-ago quarter’s reported figure.
The consensus mark for revenues stands at $42.96 billion, implying a rise of 5.28% from the prior-year quarter’s reported number.
Factors to Note
Strong performances across the company’s Evernorth, U.S. Medical and International Markets businesses are likely to have contributed to its to-be-reported quarter’s revenues.
The Evernorth unit might have gained momentum from a growing customer base and higher pharmacy scripts volumes in the to-be-reported quarter. Revenues are likely to have been driven by the insourcing of the U.S. Medical pharmacy volumes and strong organic growth including a rise in retail network and specialty pharmacy services.
Its U.S. Government business is likely to have gained from customer growth by continuing to expand its addressable markets.
The U.S. Medical business is likely to have benefited from customer growth across the company’s Select segment and Medicare Advantage business, and a rise in premiums and the return of the health insurance tax.
The International Markets business revenues are likely to have shown consistent business growth. Operating earnings might have been weighed on by costs incurred to support customers and employees, and investments made in the business for growth.
Numerous cost-curbing initiatives might have offset the company’s selling, general and administrativeexpenses to some extent in the to-be-reported quarter.
Earnings Surprise History
The company boasts an encouraging earnings surprise track. Its bottom line surpassed estimates in three of the trailing four quarters (missed the mark on the remaining occasion), the average surprise being 3.08%. This is depicted in the chart below:
What Our Quantitative Model Predicts
Our proven model does not predict an earnings beat for Cigna this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here.
Earnings ESP: Cigna has an Earnings ESP of -1.45%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Cigna currently carries a Zacks Rank #3.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Among other health insurers that have reported third-quarter results so far, the bottom-line results of UnitedHealth Group Inc. (UNH - Free Report) , Humana Inc. (HUM - Free Report) and Anthem Inc. beat the respective estimates.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Get the latest research report on UNH - FREE
Get the latest research report on HUM - FREE
Get the latest research report on CI - FREE